-+ 0.00%
-+ 0.00%
-+ 0.00%

Voyager Therapeutics says FDA clears IND for Alzheimer’s gene therapy VY1706

PUBT·06/01/2026 12:04:25
Listen to the news
Voyager Therapeutics says FDA clears IND for Alzheimer’s gene therapy VY1706
  • Voyager Therapeutics won FDA clearance of its IND for VY1706, a tau-silencing gene therapy for Alzheimer’s disease.
  • Dosing in a multi-site, open-label, dose-escalation trial is expected to start in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-068591), on June 01, 2026, and is solely responsible for the information contained therein.